For instance, elevated IL11 expression may suppress anti-tumor immune activity by fostering the development of an immunosuppressive microenvironment (Tang et al., 2024), while increased ERBB3 expression may impact immunotherapy outcomes by modulating the interplay between tumor cells and immune cells (Yang et al., 2022). Here, ERBB3 is linked to neoplasm.